Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers

Ruhisy Mohd Rasula,b, M. Tamilarasi Muniandrya,c, Zabliza Zakariaa,d, Kifayatullah Shah,e, Chin Fei Cheef, Ali Dabbaghg, Noorsaadah Abd Rahmanc, Tin Wui Wonga,d,h,*

a Non-Destructive Biomedical and Pharmaceutical Research Centre, iPROMISE, Universiti Teknologi MARA Selangor, 42300, Puncak Alam, Selangor, Malaysia
b Faculty of Applied Sciences, Universiti Teknologi MARA, 40450, Shah Alam, Selangor, Malaysia
c Department of Chemistry, Faculty of Science, University of Malaya, 50603, Kuala Lumpur, Malaysia
d Particle Design Research Group, Faculty of Pharmacy, Universiti Teknologi MARA Selangor, Puncak Alam, Selangor, Malaysia
e Department of Pharmaceutics, Faculty of Pharmacy, Gomal University, Dera Ismail Khan, Khyber Pakhtunkhwa, Pakistan
f Nanotechnology & Catalysis Research Centre, University of Malaya, 50603, Kuala Lumpur, Malaysia
g School of Medicine, Faculty of Health and Medical Sciences, Taylor’s University, Subang Jaya, Malaysia
h Sino-Malaysia Molecular Oncology and Traditional Chinese Medicine Delivery Joint Research Centre, Medical College, Yangzhou University, China

ARTICLE INFO

Keywords:
Cancer
Chitosan
Infection
Nanoparticle
Pulmonary drug delivery

ABSTRACT

Chitosan, as a biodegradable and biocompatible polymer, is characterized by anti-microbial and anti-cancer properties. It lately has received a widespread interest for use as the pulmonary particulate backbone materials of drug carrier for the treatment of infectious disease and cancer. The success of chitosan as pulmonary particulate drug carrier is a critical interplay of their mucoadhesive, permeation enhancement and site/cell-specific attributes. In the case of nanocarriers, various microencapsulation and micro-nano blending systems have been devised to equip them with an appropriate aerodynamic character to enable efficient pulmonary aerosolization and inhalation. The late COVID-19 infection is met with acute respiratory distress syndrome and cancer. Chitosan and its derivatives are found useful in combating HCoV and cancer as a function of their molecular weight, substituent type and its degree of substitution. The interest in chitosan is expected to rise in the next decade from the perspectives of drug delivery in combination with its therapeutic performance.

1. Introduction

The human lung is a biological system consisting of a series of tissues and organs that are responsible for the process of respiration (Leslie & Wick, 2018). Functionally, the lung is constituted of a conducting airway and a respiratory region. The conducting airway consists of nasal cavity, oral cavity and the associated sinuses, nasopharynx, oropharynx, larynx, trachea, bronchi, and bronchioles, whilst the respiratory region is divided into respiratory bronchioles, alveolar ducts, alveolar sacs and alveoli. The conducting airway conditions and conducts atmospheric air, while the respiratory region assists in the exchange of oxygen and carbon dioxide (Ruigrok et al., 2016). The lung provides a remarkably thin interface of approximately 0.2 μm to 0.7 μm between the alveolar lumen and capillary lumen, enabling fast and effective physiological respiration when combined with its large specific surface area (Ruigrok et al., 2016; Shah et al., 2012). The alveolar epithelium has type I and type II alveolar cells. Alveolar type I cell is a thin squamous cell acting as a barrier between air and internal components of the alveolar wall covering 95 % of the alveolar surfaces. Alveolar type II cell acts in the regeneration of type I and II cells, producing lung surfactant and covering 5 % of the alveolar surfaces (Chang et al., 2010). The alveoli surface contains brush cells and macrophages.

Inhalation is a non-invasive, organ-specific method of delivering the therapeutics to the lungs for the treatment of lung diseases (Kuzmov & Minko, 2015). Further, the cell- and organelle-specific pulmonary drug delivery can be introduced via decorating the drug carrier with specific targeting ligands (Majumder et al., 2019). The summative efforts reduce the exposure of therapeutics to healthy lung cells and other systemic organs, thereby allowing reduced drug doses and alleviating unnecessary adverse effects of drugs (Senapati et al., 2018). The pulmonary drug delivery is favourable specifically for protein and gene
based therapeutics as the lung possesses limited intracellular and extracellular drug-metabolising enzymes unlike the gastrointestinal tract and liver (Lee, Loo, Traini, & Young, 2015a, 2015b). Currently, there are four types of inhalation devices, namely pressurized metered dose inhalers, dry powder inhalers, nebulizers, and soft mist inhalers being used for the purpose of introducing pulmonary medicine by means of the inhalation route (Ruigrok et al., 2016).

The inhalation and deposition pattern of particles in lung is governed by inertial impaction, gravitational sedimentation and diffusion processes as a function of primarily the aerodynamic particle size distribution of the aerosolised therapeutics (Alhajj et al., 2020; Youngren-Ortiz et al., 2016). One of the key obstacles in pulmonary drug delivery is the high branching degree of airways with varied lengths and diameters (Fröhlich, 2019). The branched airways, gradually narrowing down from the carina of the trachea to the alveolar sac, cause the inhaled particles to hit the airway walls instead of travelling deeper into the lung as a result of an increase in the particle velocity (Lam et al., 2012). The inhaled particles fail to flow in the direction of airway branching and follow the airstream to reach the deep and peripheral lung regions (Youngren-Ortiz et al., 2016). The respiratory airway is characterized by the ciliated epithelial cells which transport mucus and alveolar fluids to the upper part of airway (Roy & Vij, 2010; Sanders et al., 2009). The mucociliary clearance is a physiological function to clear the debris, excessive secretions and any unwanted inhaled particles (Fröhlich, 2019; Yang et al., 2014). The glycosylated protein-rich mucus is constantly produced, shed and replaced to protect the lung epithelial cells from harmful particles and substances (Lai et al., 2009; Qiu et al., 2016; Yang et al., 2014). The alveolar macrophages are defence cells of the respiratory system that engulf foreign particles. The combination action of mucus and ciliary clearance with macrophage activity reduces the residence time and opportunity of particles to interact with the intended lung cell population (Ruge et al., 2013). This negates the drug delivery objective of the inhaled particles particularly when the lung cells, other than macrophages, are the target site of drug action.

### 2. Pulmonary disorders and pulmonary drug carriers

The most common lung diseases include asthma, pulmonary hypertension, chronic obstructive pulmonary disorder, acute respiratory distress syndrome in infants, cystic fibrosis, lung infections such as pneumonia and tuberculosis, and lung cancer (Alhajj et al., 2018; Paranjpe & Müller-Goymann, 2014). These diseases alter the normal physiology of the lung by airways constriction, mucus thickening, fibrosis and poor blood circulation, and hence affect the deposition profile of inhaled drugs (Borghardt et al., 2018). In most of the pulmonary disorders, the airways are sufficiently narrowed and this results in increased deposition of inhaled drugs in the upper airway by impaction (Darquenne, 2012). The residence time of particles in the lungs is mainly dependent on air flow rate, inhaled and exhaled volume, and end-inspiratory breath hold of patients. A deep, slow breathing allows a longer residence time and gives the inhaled particles much more time to deposit by sedimentation and diffusion especially at the peripheral lung (Löndahl et al., 2014). The residence time in the lungs can be further increased by end-inspiratory breath holding. The alveolar deposition increases with increasing inhaled volume or penetration depth of the aerosol into the lung. Fast and shallow breath on the other hand increases the deposition of particles in the extrathoracic airways by impaction.

Lactose receives a widespread application in the development of inhalation medicine specifically with respect to dry powder aerosol (Lee et al., 2018; Molina et al., 2018; Pinto et al., 2018; Zhou & Morton, 2012). This is attributed to stability, better flow properties and safety of lactose in dry powder inhaler formulations (Smyth & Hickey, 2005). The sugars such as lactose, mannitol, sorbitol and dextran are potentially applied as carriers in inhalational drug delivery (Odziomek et al., 2012). However, lactose is the only approved carrier in dry powder inhaler formulations (Molina et al., 2018).

The United States Food and Drug Administration (US FDA) stated two ‘points to consider’ in determining whether an FDA-regulated product involves the application of nanotechnology: (I) whether a material or end product is engineered to have at least one external dimension or an internal or surface structure, in the nanoscale range (approximately 1 nm–100 nm); or (II) whether a material or end product is engineered to exhibit properties or phenomena, including physical or chemical properties or biological effects, that are attributable to its dimension(s), even if these dimensions fall outside the nanoscale range, up to one μm (1000 nm) (Sheshala et al., 2019). With the advent of nanotechnology, the nanocarrier is recently advocated in pulmonary medicine design for the following advantages: (I) the carrier is characterized by an excessively large specific surface area that enables them to interact with the intended lung cells, (II) the carrier may be equipped with targeting ligand for cell- and organelle-specific drug targeting, (III) the cellular uptake of particles by lung cells is promoted, (IV) decrease drug dosages due to lower enzymatic activity and hence reduce side effects, and (V) improve the performance of imaging techniques applied for the in vivo diagnosis of lung cancer (Alhajj et al., 2018; Smola et al., 2008).

### 3. Chitosan

Chitin is considered as one of the major sources of nitrogen accessible to countless terrestrial and aquatic organisms (Elieh-Ali-Komi & Hamblin, 2016). It is a major constituent of the exoskeleton of many arthropods like insects, spiders and crustaceans and the internal structures of other invertebrates (Brigham, 2018). The chitin is constituted of β (1→4) linked residues of N-acetyl-2-amino-2-deoxy- D-glucose and 2-amino-2-deoxy- D-glucose (Elieh-Ali-Komi & Hamblin, 2016). It exhibits an extremely poor aqueous solubility due to its highly crystalline characteristics which are brought about via hydrogen bonding between the acetamido moieties (Uto et al., 2018; Zhu et al., 2016). The partially deacetylated chitin is water-soluble (Muzzarelli et al., 1999; Ying et al., 2011). The lowest possible degree of deacetylation in chitin can be less than 10 % with molecular weight as high as

![Chemical structures of (a) chitin and (b) chitosan.](image-url)
Table 1
Selected examples of chitosan derivatives.

| Chitosan derivative                        | Remark                                                                 | Reference                                                                                     |
|-------------------------------------------|------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| **Cationic chitosan**                     | Highly positively charged.                                              | (Avadi et al., 2004; Cano-Cebrian et al., 2005; Ding et al., 2006; Fee et al., 2003; Guo et al., 2006, 2007; Holappa et al., 2006; Je & Kim, 2005; Jia et al., 2001; Kotze et al., 1997; Lee et al., 2002; Lim & Hudson, 2004; Rinazessson et al., 2007; Singla & Chawla, 2001) |
| i.e. Trimethyl chitosan chloride, N-[2-hydroxy-3-trimethyl-ammonium]-propyl] chitosan chloride, N-propyl-N,N-dimethyl chitosan, N-furfuryl-N,N-dimethyl chitosan, N-diethylmethylamino chitosan. | Strong film forming properties.                                        |                                                                                               |
|                                            | Compatible with cations.                                               |                                                                                               |
|                                            | Forms complexes with anions.                                           |                                                                                               |
|                                            | Improved aqueous solubility at pH < 9.                                  |                                                                                               |
|                                            | Enhanced intestinal permeation property.                               |                                                                                               |
|                                            | Improved mucoadhesive property.                                       |                                                                                               |
|                                            | Biodegradable.                                                        |                                                                                               |
|                                            | Cytotoxic.                                                            |                                                                                               |
|                                            | Anti-bacterial.                                                       |                                                                                               |
|                                            | Anti-fungal.                                                          |                                                                                               |
|                                            | Potent hydroxyl radical scavenger.                                    |                                                                                               |
|                                            | Hydroscopic.                                                          | (Guo et al., 2006; Hu et al., 2007; Lee et al., 2002; Mansouri et al., 2006; Ravi Kumar, 2000; Xiangyang et al., 2007) |
|                                            | Biodegradable.                                                        |                                                                                               |
|                                            | Amphiphatic hydrogel with excellent water absorption and water retention abilities. | (Badawy et al., 2005; Mourya & Inamdar, 2008; Zariwala et al., 2018)                             |
|                                            | Anti-cancer drug carrier.                                              |                                                                                               |
|                                            | Anti-bacterial.                                                       |                                                                                               |
|                                            | Cyto-compatible with chondrocytes.                                     |                                                                                               |
|                                            | Excellent transfection efficiency.                                    |                                                                                               |
|                                            | Facilitated endocytic uptake.                                         |                                                                                               |
|                                            | Organosoluble.                                                        | (Kogan et al., 2004; Mourya & Inamdar, 2008; Muzzarelli et al., 1999)                         |
|                                            | Promote enzymatic hydrolysis.                                         |                                                                                               |
|                                            | Fungicidal.                                                           | (Kogan et al., 2004; Mourya & Inamdar, 2008; Muzzarelli et al., 1999)                         |
|                                            | Improved mucoadhesive and absorptive properties.                      |                                                                                               |
|                                            | Possess high cellular permeability.                                   |                                                                                               |
|                                            | Soluble in water.                                                     |                                                                                               |
|                                            | Show high viscosity and large hydrodynamic volume and film gel forming capacity. |                                                                                               |
|                                            | Possess good chelating abilities.                                     |                                                                                               |
|                                            | Antioxidant.                                                          |                                                                                               |
|                                            | Anti-mutagenic.                                                       |                                                                                               |
|                                            | Anti-bacterial.                                                       | (Mourya & Inamdar, 2008; Zhu & Fang, 2005)                                                   |
| **N-Acylchitosan**                        | Improved mucoadhesiveness.                                            | (Bernkop-Schnürch & Kast, 2001; Füger et al., 2006; Hassan & Gallo, 1990; Kast et al., 2003; Krauland et al., 2004; Leitner et al., 2003; Maculotti et al., 2005; Roldo et al., 2004) |
| i.e. Formyl, acetyl, propionyl, butyryl, hexanoyl, octanoyl, decanoyl, carbamoyl, succinyl, acetoxybenzoyl chitosans. | Improved permeation enhancement properties.                           |                                                                                               |
|                                            | Improved adhesive properties.                                         |                                                                                               |
|                                            | Enhanced chondrocyte adhesion.                                        |                                                                                               |
|                                            | Enhanced blood compatibility.                                         |                                                                                               |
| **O-Acylchitosan**                        | Improved mucoadhesiveness.                                            | (Bernkop-Schnürch & Kast, 2001; Füger et al., 2006; Hassan & Gallo, 1990; Kast et al., 2003; Krauland et al., 2004; Leitner et al., 2003; Maculotti et al., 2005; Roldo et al., 2004) |
| i.e. O-succinylchitosan, O-palmitoyl chitosan, O,O-didecanoylchitosan. | Improved permeation enhancement properties.                           |                                                                                               |
|                                            | Improved adhesive properties.                                         |                                                                                               |
|                                            | Enhanced chondrocyte adhesion.                                        |                                                                                               |
|                                            | Enhanced blood compatibility.                                         |                                                                                               |
| **N-Carboxyalkyl/aryl chitosans**         | Improved mucoadhesiveness.                                            | (Bernkop-Schnürch & Kast, 2001; Füger et al., 2006; Hassan & Gallo, 1990; Kast et al., 2003; Krauland et al., 2004; Leitner et al., 2003; Maculotti et al., 2005; Roldo et al., 2004) |
| i.e. N-carboxymethyl chitosan, N-carboxypropyl chitosan, N-carboxybenzyl chitosan, N-(2-carboxyethyl)chitosan. | Improved permeation enhancement properties.                           |                                                                                               |
|                                            | Improved permeation enhancement properties.                           |                                                                                               |
|                                            | Possess cohesive and in situ gelling properties.                      |                                                                                               |
|                                            | Biodegradable.                                                        |                                                                                               |
|                                            | Possess enzyme inhibitory properties.                                 |                                                                                               |
| **O-Carboxyalkyl chitosan**               | Improved mucoadhesiveness.                                            | (Bernkop-Schnürch & Kast, 2001; Füger et al., 2006; Hassan & Gallo, 1990; Kast et al., 2003; Krauland et al., 2004; Leitner et al., 2003; Maculotti et al., 2005; Roldo et al., 2004) |
| i.e. O-carboxymethyl chitosan, cross-linked O-carboxymethyl chitosan. | Improved permeation enhancement properties.                           |                                                                                               |
|                                            | Improved permeation enhancement properties.                           |                                                                                               |
|                                            | Possess cohesive and in situ gelling properties.                      |                                                                                               |
|                                            | Biodegradable.                                                        |                                                                                               |
|                                            | Possess enzyme inhibitory properties.                                 |                                                                                               |
| **Thiolated chitosan**                    | Improved mucoadhesiveness.                                            | (Bernkop-Schnürch & Kast, 2001; Füger et al., 2006; Hassan & Gallo, 1990; Kast et al., 2003; Krauland et al., 2004; Leitner et al., 2003; Maculotti et al., 2005; Roldo et al., 2004) |
| i.e. Chitosan-cysteine, chitosan-thioglycolic acid, chitosan-4-thiobutylamidine, chitosan-thioethylamidine, chitosan-2-iminothiolane conjugates. | Improved permeation enhancement properties.                           |                                                                                               |
|                                            | Improved permeation enhancement properties.                           |                                                                                               |
|                                            | Possess cohesive and in situ gelling properties.                      |                                                                                               |
|                                            | Biodegradable.                                                        |                                                                                               |
|                                            | Possess enzyme inhibitory properties.                                 |                                                                                               |
| **Sugar linked chitosan**                 | Water-soluble.                                                        | (Morimoto et al., 2001; Mourya & Inamdar, 2008; Sashiwa & Aiba, 2004; Zhang et al., 2010)     |
| i.e. lactosaminated                        | Cell-, virus- and bacteria-specific as a function of sugars characteristics. |                                                                                               |
|                                            | Possess intercellular recognition and adhesion.                       |                                                                                               |

(continued on next page)
1–2.5 × 10^6 Da and parallel to a degree of polymerization of approximately 5000–10000 monomeric residues (Chawla et al., 2015).

Chitosan is the most important derivative obtained by N-deacetylation of chitin with hot alkali (Fig. 1) (Antonino et al., 2017).

The degree of deacetylation of chitosan ranges from 40 % to 98 % with its molecular weight ranging between 5 × 10^4 Da and 2 × 10^6 Da (Fig. 1) (Antonino et al., 2017; Chawla et al., 2015; Hejazi & Amiji, 2003; Mourya & Inamdar, 2008). Deacetylation of chitin provides chitosan with free amino functional groups that are readily protonated to induce polymer solubilisation or chemically reacted and grafted to produce new chitosan derivatives with specific physicochemical and biological properties (Table 1).

Unlike lactose disaccharide, the chitosan is a polysaccharide. The chitosan has multiple functional groups such as N–H and OH– that render it flexibly being modified for specific pharmaceutical or medical purposes (Kyzas & Bikiaris, 2015). The cationic amino moieties at the C2 position of the repeating units of chitosan readily interact electrostatically with anionic groups of other polymers to form polyelectrolyte complexes (Kulig et al., 2016). Chitosan has been complexed with various natural polyanions such as pectin, alginate, xanthan gum, carrageenan, chondroitin sulphate, carbomymethyl cellulose, hyaluronic acid, dextran sulphate or synthetic polyions like poly (acrylic acid), poly (L-lactide) and polyphosphoric acid to confer specific drug delivery properties (Arriagada et al., 2004; Gnavi et al., 2013; Hamman, 2010; Quíñones et al., 2018). Through varying its molecular weight and degree of deacetylation, the chitosan can be transformed into nano-carrier with the intended sizes and zeta potentials (Mao et al., 2010). Chitosan is a plastic material which is mouldable into amorphous forms (Dang et al., 2017). Its molecular chains can be compacted at nanoscale as a function of formulation and processing conditions via hydrogen bonding, electrostatic interaction and/or Van der Waals forces (Zhang et al., 2015). Being polysaccharidic, chitosan is mucoadhesive and possesses visous attribute that is essential in drug encapsulation, drug release and drug absorption kinetics modulation (Quíñones et al., 2018). As a cationic polyelectrolyte, the chitosan has a high affinity for the negatively charged mucosal interface that is rich in sialic acid and O-sulfosaccharides (Zhang et al., 2015). Chitosan is able to reduce the transepithelial electrical resistance of epithelial membranes by disrupting tight junctions between the epithelial cells (Yeh et al., 2011). It can loosen the tight junction of mucosa via the translocation of tight junction proteins from the membrane to the cytoskeleton through Protein Kinase C pathway, thereby promoting drug transport para-cellularly and transcellularly (Rosenthal et al., 2012; Smith et al., 2004; Smith et al., 2005). Chitosan is biodegradable and biocompatible (Rodrigues et al., 2012; Saber et al., 2010). It is known as a therapeutic polymer which possesses anti-cancer (Azuma et al., 2015), anti-bacterial (Goy et al., 2009; Kara et al., 2014; Rabea et al., 2003), antifungal (Menconi et al., 2014; Tayel et al., 2010; Verlee et al., 2017), anti-oxidative (Ngo et al., 2015), anti-inflammatory (Azuma et al., 2015) and anti-diabetic activities (Liu et al., 2010; Ngo et al., 2015). On this note, the potential of chitosan for use in the development of pulmonary medicine is deemed to be higher than that of lactose. With reference to cancer nanomedicine, the physicochemical attributes of the chitosan-based drug carrier such as size, shape, surface charge, surface morphology, targeting ligand availability and its nature are found to critically dictate the effectiveness of cell targeting, internalization and anti-tumour action of cancer therapeutics (Musalli et al., 2020; Wang et al., 2017). Small, spherical and positively charged nanocarriers with reduced surface area to interrupt the cancer cell membrane and enhanced affinity for the negatively charged cancer cell surfaces favour cellular uptake. The use of a sublevel or an excessive fraction of targeting ligand translates to inadequate nanocarrier-cancer cell surface receptor interaction and poor intracellular therapeutic availability due to insufficient ligand or steric hindrance of overcrowded ligands in receptor binding. Similar findings are observed in the case of infection nanomedicine. In infectious diseases such as pulmonary tuberculosis, drug targeting at the alveolar macrophages is of paramount importance as these are the residence site of tubercle bacilli (Shah et al., 2017). The hydrophobic carrier exhibits a higher degree of opsonisation by macrophages. The nanocarrier made of high molecular weight or viscosity chitosan can hinder transmembrane drug transport into the macrophages (Mohd Chachuli et al., 2016). This nanocarrier can bind to the extracellular membrane of macrophages and develop a viscous barrier to drug diffusion or endocytosis.

4. Pulmonary infectious diseases and the applications of chitosan based carriers

Pulmonary infection represents one of the significant burdens to healthcare system worldwide, and this includes infection caused by bacteria (Mycobacterium tuberculosis, Pseudomonas aeruginosa, Streptococcus pneumonia), fungi (Aspergillus fumigates) and viruses (influenza virus A, influenza virus B, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) (Brenner et al., 2011; Muttill et al., 2009; Wang et al., 2020; Wu et al., 2020). The infection can be fatal in immuno-compromised patients and those with underlying pulmonary dysfunctions (Merchant et al., 2016). The infection mostly involves treatment with anti-inflammatory and anti-infective agents. Conventionally, these drugs are commonly delivered via oral or parenteral routes. The systemic administration of drugs may be accompanied by inadequate drug concentration at the site of the infected lung, rapid declination of plasma drug concentration to sub-therapeutic level and development of microbial resistance. Local drug delivery by inhalation is envisaged to resolve such hurdles. Drug delivery system development using chitosan is foreseeable to benefit from its anti-microbial activity. The chitosan is mucoadhesive (Oliveira et al., 2017). It can bind to the lipopolysaccharides and phosphoryl groups of the bacterial cell membrane via its protonated amino moieties (Garg et al., 2015; Mohammed...
et al., 2017; Park et al., 2010). The adhesion elicits intracellular transductions of enzymes and blockage of electron transport, membrane perforation and intracellular electron leakage which eventually destroy or prevent the growth of bacterial cells (Dutta et al., 2012; Pourshahab et al., 2011; Rabea et al., 2003). The other proposed mechanism is the binding of chitosan with microbial DNA, which leads to the inhibition of the mRNA and protein synthesis via the penetration of chitosan into the nuclei of the microorganisms (Goy et al., 2009; Sebti et al., 2005). The positively charged chitosan can also interfere with the microbial growth by selectively binding with the essential nutrients of microbes (Chen et al., 2002; Jia et al., 2001). The low molecular weight chitosan with higher degrees of deacetylation and charge densities is reported to exhibit a higher level of anti-microbial activity (Goy et al., 2009; Kong et al., 2010; Park et al., 2010). The negative charge on the cell surface of the gram-negative bacteria is higher than that of gram-positive bacteria (Chung et al., 2004; Tayel et al., 2010). The former is relatively hydrophilic thereby leading to more chitosan being adsorbed onto the cell surfaces and having them experiencing a higher growth inhibitory effect.

Tuberculosis is a chronic granulomatous airborne bacterial infection caused by M. tuberculosis (Mehta et al., 2018). This contagious infectious disease occurs through inhalation of Tubercle bacilli infected droplets present in the size range of 1 μm–5 μm, that remain suspended in the air from minutes up to several hours (Fernstrom & Goldblatt, 2013; Muttli et al., 2009). The small size of droplet nuclei enables them to evade bronchial defense system and reach the alveoli (Pham et al., 2015). The bacterium can be engulfed by alveolar macrophages, replicated intracellularly and further infected the surrounding cells before the development of an immune response (Khinikar et al., 2010). The M. tuberculosis has a tendency to infect non-phagocytic cells present in the alveolar region such as M cells, epithelial cells and alveolar endothelial cells. The disease mostly affects the lung and remains localized in 75–80% of the cases (Cosnik et al., 2010; Yadav et al., 2009). It can also disseminate to other areas causing extra pulmonary tuberculosis. The primary infection can progress towards active disease, remain as latent infection or be eradicated by the immune system of the host (Gengenbacher & Kaufmann, 2012). The efficacy of currently available drugs (isoniazid, rifampicin, ethambutol and pyrazinamide) is complicated by the development of an immune response (Lee et al., 2018; Smyth & Hickey, 2005). Blending of such microparticles with larger carriers of sizes between 63 and 90 μm can aid to disaggregate the microparticulate structures through the surface adsorption phenomenon (Lee et al., 2018; Smyth & Hickey, 2005). The large carrier serves as the pulmonary vehicle of microparticles and the detachment of microparticles from large carrier in lung renders drug/nanoparticles deposition at the intended target site (Gramejeijer et al., 2014; Renner et al., 2017; Zeng et al., 2006; Zeng et al., 2001; Zhou & Morton, 2012). Blending of nanoparticles with microparticles brings similar advantages in powder flow as that of the mix of microparticles and large carriers (Alhajj et al., 2020). Individually, both nanoparticles and microparticles are cohesive. Blending of them in specific weight ratios reduces the nanoparticulate aggregation through dispersing the nanoparticles over the surfaces of the microparticles. The adsorbed nanoparticles can act as a glidant. Their presence on microparticulate surfaces reduces the aggregation tendency of the microparticles, thereby producing an inhalable powder with an appropriate flow property.

With reference to direct blending of chitosan nanoparticles with lactose based microparticles, it is found that the size, shape and specific surface area of the nanoparticles have a strong bearing on the inhalation efficiency of the nanoparticles (Alhajj et al., 2020). Small and irregularly shaped nanoparticles with a large specific surface area tend to aggregate among themselves instead of depositing onto the microparticulate surfaces. As a result, their inhalation propensity to deep and peripheral lungs has been found to be lower than those of larger and rounder nanoparticles. Direct blending of nanoparticles with microparticles is envisaged to circumvent several drug delivery hurdles of the microencapsulated nanoparticles (Alhajj et al., 2020; Garbuzenko et al., 2014; Mehta, 2016). Unlike the microencapsulated systems, the changes in nanoparticulate sizes are less likely with blending thus the size-dependent biological performances of the nanoparticles are less affected (Alhajj et al., 2020). The blending system is characterized by nanoparticles depositing onto the surfaces of the microparticles (Alhajj et al., 2020). The nanoparticles have a high level of redispersibility. They can be detached and inhaled into the lung targets with lower risks of being captured in the core of the microencapsulated vehicle without them releasing to the lung targets.

In the case of nanoemulsion, it is delivered via the pulmonary route by means of nebulization approach (Amani et al., 2010). Liquid dosage form such as nanoemulsion commonly exhibits a high level of dispersion and inhalation to peripheral lungs (Amani et al., 2010; Shah et al., 2017). The alveolar macrophages are characterized by cell surface leptin receptor of mannose specificity (Filatova et al., 2018). The chitosan is known to be able to be recognized by alveolar macrophages. The nanoemulsion droplets have been decorated with chitosan to enable drug targeting at macrophages which harbor T. bacilli (Shah et al., 2017). The folate receptors are also expressed on the cell surfaces of activated alveolar macrophages (Jain et al., 2013). Decoration of nanoemulsion droplets by chitosan and folate in the form of a covalent conjugate has been found to enhance the endocytosis of particles into the macrophages and lung drug retention (Shah et al., 2017). The dual receptor targeting is more effective than single receptor strategy, and is expected to bring about a higher degree of bacteria eradication from the macrophages and infected lung.

The derivatives of chitosan such as carboxymethyl chitosan and octanoyl chitosan have been synthesized with the aim to prepare the nanocarrier of anti-tubercular drugs (Petkar et al., 2018). The mono-N-carboxymethyl chitosan has been reported to be able to decrease the transepithelial electrical resistance of Caco-2 cell monolayers thereby can act as a membrane permeation enhancer (Jayakumar et al., 2010). The acylation of chitosan using acyl chlorides and anhydrides confers organic solubility and increases the hydrophobicity of chitosan without incurring cytotoxicity. The hydrophobic octanoyl chitosan has been used to prepare crosslinker-free nanoparticles by means of double
Table 2
Pulmonary chitosan carriers of drugs for the treatment of infectious diseases.

| Code | Formulation and Preparation | Physicochemical Property | Aerodynamic Property | Cell Culture / Microbial Examination | In Vivo Performance | Remark | Reference |
|------|-----------------------------|--------------------------|----------------------|-------------------------------------|--------------------|--------|-----------|
| F1   | Second line anti-tubercular drug |
|      | “prothionamide” loaded chitosan nanoparticles are prepared by ionic gelation technique, followed by freeze-drying into dry powder inhalational formulation. To increase the flow property, prothionamide nanoparticles and anhydrous inhalable grade lactose are mixed (1:0.5, 1:1, 1:1.5 weight ratio etc.) manually using a geometrical dilution process. | Spherical particles of 314.37 ± 3.68 nm with a zeta potential value of 32.40 ± 104 mV are produced. The freeze dried nanoparticles are fluffy with a fair flow property. These nanoparticles are characterized by angle of repose, Carr’s index and Hausner ratio as 37.32°, 17.43 % and 1.21 respectively. Their flowability improves through blending with lactose in 1:1 weight ratio, with angle of repose, Carr’s index and Hausner ratio of 29.25 ± 2.15°, 9.8 ± 2.1 % and 1.11 ± 0.01 respectively. In vitro initial burst drug release followed by sustained release up to 96.91 % in 24 h is noted. | Emitted dose of 82.37 %, aerodynamic particle size of 1.76 μm, geometric standard particle size distribution of 1.96 and fine particle fraction of 81.19 % are reflected in Anderson cascade impactor study. | Nil | Animal study using single dose administration through mono-dose inhaler indicates that prothionamide nanoparticles loaded dry powder inhalation achieves C_{max} 290 ± 0.28 μg/mL at T_{max} 3 h. The dry powder inhalation of prothionamide nanoparticles maintains the plasma drug concentration above the minimum inhibitory concentration for a period more than 12 h, unlike pure drug which could only maintain for up to 3 h. | Stability study shows no significant changes in polydispersity index, zeta potential, drug entrapment efficiency and percent drug release. In vitro drug release finding is reflected in the in vivo pharmacokinetics study. | (Debnath et al., 2018) |
| F2   | Isoniazid (INH) and rifampin (RMP) loaded gemipin-crosslinked carboxymethyl chitosan (GEN-CS) nanogel is prepared using emulsion crosslinking method, washed with ultrapure water, ultra-filtered and vacuum dried. | Spherical homogeneous particles of 60 nm–130 nm with positive zeta potential are produced. The drug loads of INH and RMP are 92.7 μg/mg and 66.1 μg/mg, respectively. The particles show sustained drug release behaviour in the simulated lung fluid. | The nanoparticles have a relatively high anti-bacterial activity against multidrug-resistant tuberculosis at reduced cytotoxicity of drugs. | Nil | The GEN-CS/INH/RMP nanogel provides a predominant deposition of drug within the lung of animals when the nanogel particles are administered using a dried powder insufflator. To prepare GEN-CS nanogel for the encapsulation of INH and RMP, the GEN, which serves as the crosslinker, is 5000 to 10,000 times less cytotoxic than glutaraldehyde. The nanogel provides a safe and efficient administration of anti-tubercular drugs. | (Wu et al., 2018) |
| F3   | Rifampicin loaded octanoyl chitosan nanoparticles are produced by double emulsion solvent evaporation technique. Nanoparticles obtained are then lyophilized following the addition of 1%w/v trehalose dehydrate as the cryoprotectant. | The octanoyl chitosan nanoparticles have smooth surface texture and spherical morphology, with diameter of 253 ± 19.06 nm, polydispersity index of 0.323 ± 0.059 and drug entrapment efficiency of 64.86 ± 7.73 %. Sustained drug release behaviour within 72 h of dissolution (73.14 ± 3.17 %) is noted. | The two-stage impinger analysis of the lyophilized rifampicin loaded octanoyl chitosan nanoparticles proceeds through dispersing the nanoparticles in 5 ml water and aerosolising from a jet nebulizer at 60 L/min. The nebulization efficiency is 77.04 ± 4.33 %, with a fine particle fraction of 43.27 ± 4.24 %. | Preliminary cytotoxicity studies of nanoparticles show no observable effect on cell viability over a period of 24 h on A549 cell lines. | Nil | The nanoparticles are physically stable for 2 months. They show excellent aerosolisation profile and sustained drug release characteristics. | (Petkar et al., 2019) |
| F4   | Rifampicin-oic acid first-generation nanoemulsion and its respective chitosan- and chitosan-folate conjugate-decorated second and third generation nanoemulsions are prepared by spontaneous emulsification technique. | The nanoemulsions have average droplet sizes of 40 nm–60 nm, with narrow polydispersity indices. They exhibit desirable pH, surface tension, viscosity, refractive index, density and viscosity attributes for pulmonary administration. Nanoemulsions demonstrate more than 95 % aerosol output with an inhalation efficiency greater than 75 %. The aerosol output and inhaled fine particle fractions are primarily governed by the size and surface tension of nanoemulsions in an inverse relationship. | A significantly higher level of internalisation of nanoemulsion by alveolar macrophages is observed with third generation nanoemulsions than second generation nanoemulsion at 2 h of incubation due to dual receptor targeting of macrophage by means of chitosan and folate. The cell viability in NR8383 cells is above 80 %. The percentage of J774 macrophage cell viability is | The intratracheal administration of the nanoemulsions depicts that first and third generation nanoemulsions attain higher plasma drug concentrations in the first hour due to higher levels of burst drug release. The second generation nanoemulsion demonstrates sustained plasma drug level in vivo. | To prepare GEN-CS nanogel for the encapsulation of INH and RMP, the GEN, which serves as the crosslinker, is 5000 to 10,000 times less cytotoxic than glutaraldehyde. The nanogel provides a safe and efficient administration of anti-tubercular drugs. | (Shah et al., 2017) |
| F5   | Rifampicin loaded chitosan nanoparticles are prepared by | Particles of 124.1 ± 0.2–402.3 ± 2.8 nm with drug entrapment Hauser ratio of nanoparticles is 1.22 ± 1.2. A fine particle | | | A marked increase in maximum plasma drug concentration is | The freeze-dried rifampicin nanoparticles act as a better | (Rawal et al., 2017) |

(continued on next page)
| Code | Formulation and Preparation | Physicochemical Property | Aerodynamic Property | Cell Culture / Microbial Examination | In Vivo Performance | Remark | Reference |
|------|-----------------------------|--------------------------|----------------------|--------------------------------------|---------------------|--------|----------|
| F6   | Isoniazid and rifampicin loaded chitosan nanoparticles are prepared by ionic gelation followed by spray drying processes. | Efficiency of 72.0 ± 0.1 % and sustained drug release behaviour (in vivo release of 100 % pure drug within 12 h and approximately 90 % release of encapsulated rifampicin within 24 h) are produced. | Fraction of 33.27 ± 0.87 % with a mass median aerodynamic diameter of 3.3 ± 0.18 μm are attained in Andersen cascade impactor analysis. | Nil | Higher with nanoparticles (80-90 %) than pure rifampicin (75-80 %) at the drug dosage of 0.125 mg/mL | Nil | Administration of nebulized nanoparticles for 28 days to M. tuberculosis infected mice results in undetectable mycobacterial colony forming unit in lung and spleen homogenates. A compressor nebulizer system is used in this study to administer drugs in aerosol to female Balb/c mice (20–30 g/mouse). Both drugs are detected in various organs (lung, liver, spleen and kidney) until 24 h post nebulization. The high lung drug concentration is attributed to drug retention via phagocytosis by macrophages. The chitosan nanoparticles provide an effective drug targeting to macrophage-rich organ that is essential in tuberculosis treatment. | (Garg et al., 2015) |
| F7   | Rifampicin loaded chitosan-polyactic acid-polyethylene glycol-gelatin nanoparticles are prepared by emulsion solvent evaporation technique. | Spherical and compact particles where size increases with increasing concentration of rifampicin (187 ± 10 nm to 214 ± 17.3 nm) and co-polymers (192 ± 8.5 nm to 234 ± 16.8 nm) are produced. The zeta potential increases from 21 ± 2.2 mV to 29 ± 1.6 mV with an increase in rifampicin concentration from 10 % to 50 %. The drug entrapment efficiency of nanoparticles improves with the use of copolymers where 96.8 % is achieved in the composite containing polyactic acid, polyethylene glycol and gelatin. The initial drug release is fast and declined thereafter. | Nil | Administration of nebulized nanoparticles for 28 days to M. tuberculosis infected mice results in undetectable mycobacterial colony forming unit in lung and spleen homogenates. A compressor nebulizer system is used in this study to administer drugs in aerosol to female Balb/c mice (20–30 g/mouse). Both drugs are detected in various organs (lung, liver, spleen and kidney) until 24 h post nebulization. The high lung drug concentration is attributed to drug retention via phagocytosis by macrophages. The use of copolymers is deemed beneficial in drug entrapment within the nanoparticulate system, and it provides a slow late phase of drug release. | Nil | | (Rajan & Raj, 2013) |
The fine particle fraction of lactose containing powders is higher than mannitol and maltodextrin.

The minimum inhibitory concentration of tests using isoniazid solution is about 16 times higher than that of the powdered formulation. The introduction of leucine improves the fine particle fraction and the anti-bacterial activity of drug aerosolized from all formulations due to the production of smaller drug loaded nanoparticles.

Table 2 (continued)

| Code | Formulation and Preparation | Physicochemical Property | In Vivo Performance | Cell Culture / Microbial Examination | Remark |
|------|----------------------------|--------------------------|--------------------|--------------------------------------|--------|
| F9   | Isoniazid loaded chitosan nanoparticles are prepared by spray drying method. | Spherical, hexagonal and rod shaped particles with a size of 3 μm–5 μm. | Emitted dose of 46 % to 90 % are attained. | The viability of cells treated with drug loaded microparticles at 0.5 mg/mL and 10 mg/mL concentrations varies from 70 % to 90 % in human Caucasian lung (Calu-3) cell line. | Nil |
| F10 | Doripenem loaded chitosan microparticles are prepared by spray drying method. | Surface-porous particles of 3.8–6.9 μm that are spherical and exhibit a mass median aerodynamic diameter of 4.11 μm, a geometric standard deviation of 2.11 and a fine particle fraction of 27.6 %. | The viability of cells treated with drug loaded microparticles is 98 % at 0.5 mg/mL concentrations, with positive zeta potential (+17.7 mV). | The microspheres are envisaged to be able to reach the conductive agent. | Nil |
| F11 | Doripenem loaded chitosan microparticles with different microparticle size distribution prepared by spray drying method. | 3 μm–5 μm in size, with or without crosslinking. | Released in 3 h of dissolution, and almost all content of drug are released in 24 h. | The anti-bacterial efficacy of microspheres against the drug is 99.5 %. | Nil |
| F12 | Levofloxacin loaded chitosan microspheres are prepared by spray drying method. | 2 μm–5 μm in size, with or without crosslinking. | Released in 3 h of dissolution, and almost all content of drug are released. | The microspheres are envisaged to be able to reach the conductive agent. | Nil |
emulsion solvent evaporation technique for pulmonary delivery of rifampicin. The positively charged nanoparticles are equipped with drug release controlling ability of octanoyl derivative, and higher mucoadhesive and membrane permeation enhancement properties along with resistance to enzymatic degradation than that of plain chitosan (Ahmed & Aljaeid, 2016; Petkar et al., 2018). The chitosan based nanoparticles are electrostatically attracted to the negatively charged sialic acid present on the surfaces of lung alveolar macrophages. An enhancement in the binding affinity between the nanoparticles and the macrophages leads to a greater extent in uptake of drug and nanoparticles by the alveolar macrophages harboring the T. bacilli (Rawal et al., 2017). Both passive membrane adhesion and active receptor binding of nanoparticles are promotable with the use of particulate carrier characterized by positive surface charges.

Cystic fibrosis is an inherited autosomal recessive disease of the lung characterized by the production of viscid mucus which leads to the dysfunction of lung microorganism clearance system (Garbuzenko et al., 2019). The chronic inflammation and bacterial infection specifically by P. aeruginosa result in respiratory failure of the cystic fibrosis patients (Ng et al., 2014). Tobramycin, aztreonam and colistimethate, a prodrug of colistin, are available as inhalational products that represent a valuable alternative to solution for injection or oral therapy. Phase 2b trial of levofloxacin inhalation solution demonstrates that the sputum content of P. aeruginosa is reduced with the lung function improved in cystic fibrosis patients (Gaspar et al., 2015; Stockmann et al., 2014). The inhaled formulations with an aerodynamic diameter of 1 μm–5 μm are suitable for deep lung deposition, but particles of 1 μm–5 μm are also favorably phagocytosed by the resident macrophages. This poses toxicity to macrophages and could have reduced the availability of drug at the intended target site. The inhaled microparticles are designed with the ability to swell upon hydration following their deposition in the lung epithelial lining fluid in order to bypass macrophage uptake (Chaubey & Mishra, 2014). Chitosan as a swellable biopolymer, on this note, have been effectively utilized in the development of inhalable dosage forms for cystic fibrosis treatment (Table 2). Ortiz, Jornada, Pohlmann, and Guterres (2015) report that the use of chitosan in the form of microparticulate carrier of dapsone does not promote cytotoxicity in J774 macrophages and pulmonary cell damage as indicated by low levels of cytosolic lactate dehydrogenase and membrane bound alkaline phosphatase in the bronchoalveolar lavage fluid.

5. Lung cancer and the applications of chitosan based carriers

The global incidence of cancer rises to 18.1 million newly diagnosed cases, with 9.6 million deaths in 2018 (Bray et al., 2018). Lung cancer is one of the major causes in worldwide cancer related mortalities (Wang et al., 2017). It is histologically divided into small cell lung carcinoma and non-small cell lung carcinoma representing 96 % of the cases, and mesothelioma, carcinoid, and sarcoma (Alhajj et al., 2018). The small cell lung carcinoma (20 %) and non-small cell lung carcinoma (80 %) differ from each other in sizes and locations in lung. The small cell lung carcinoma is located in central lung, while non-small cell lung carcinoma is located from central to peripheral lungs. The standard treatment option of lung cancer involves chemotherapy, surgery or radiotherapy depending on the stage of malignancy. Chemotherapy with drugs like gemcitabine, cisplatin, paclitaxel, docetaxel and vinorelbine is considered one of the first options that are mostly administered systemically (Paumier & Le Péchoux, 2010). These drugs are associated with serious side effects like pain, nerve damage and skin allergic reactions (Lee et al., 2015a). With reference to the intravenous paclitaxel, the solubilizing mixture of Cremophor EL and dehydrated alcohol has also been ascribed as the cause of drug hypersensitivity reaction and neurotoxicity (Gelderblom et al., 2001). Local administration of anticancers drugs via inhalation can reduce the systemic adverse effects with optimum drug concentration attainable at the target site. In 1993, one of the first clinical studies on pulmonary administration of a
Table 3
Pulmonary chitosan carriers of drugs for the treatment of cancer.

| Code | Formulation and Preparation | Physicochemical Property | Aerodynamic Property | Ex Vivo / Cell Culture Performance | In Vivo Performance | Remark | Reference |
|------|-----------------------------|--------------------------|----------------------|-----------------------------------|-------------------|--------|-----------|
| F1   | Paclitaxel (PTX) and quercetin (QUE) loaded nanoparticles are prepared using oleic acid-chitosan complex (OA-C) as the carrier by ionic crosslinking method. The aqueous dispersion of PTX-OA-C nanoparticles, QUE-OA-C nanoparticles, polymeric microspheres are 226.1 nm, 246.5 nm, 247.4 nm and 3.373 μm respectively. The polydispersity index ranges from 0.123 to 0.456 with zeta potential of 32.9 mV, 24.2 mV and 26.0 mV for OA-C nanoparticles, PTX-OA-C nanoparticles and QUE-OA-C nanoparticles respectively. A burst drug release followed by a sustained release behaviour up to 48 h are attained with polymeric microspheres in both pH 7.4 and pH 4.5 release medium. | The particle sizes of OA-C nanoparticles, PTX-OA-C nanoparticles, QUE-OA-C nanoparticles and polymeric microspheres are 226.1 nm, 246.5 nm, 247.4 nm and 3.373 μm respectively. The polydispersity index ranges from 0.123 to 0.456 with zeta potential of 32.9 mV, 24.2 mV and 26.0 mV for OA-C nanoparticles, PTX-OA-C nanoparticles and QUE-OA-C nanoparticles respectively. | The in vivo pharmacokinetics analysis in rats depicts that the time to reach maximum plasma drug concentration, drug half-life and AUC of PTX and QUE are higher with pulmonary administration of polymeric microspheres than those of combined or single intravenous administration of PTX and QUE. The clearance and peak plasma drug concentration are lower with the use of pulmonary polymeric microspheres. | Nil | The polymeric microspheres act as a platform to deliver the nanoparticles to lungs, with mannitol and lactose serving as disintegrant to release the nanoparticles at the target site. The OA-C nanoparticles, PTX-OA-C nanoparticles and QUE-OA-C nanoparticles are adopted to promote cellular drug uptake via nanogeometry of particles and permeation enhancement property of oleic acid. | (Liu et al., 2017) |
| F2   | 3,4,5-tribenzyloxybenzoic acid (GAOBn) loaded gold nanoparticles stabilized by quaternized chitosan-gallic acid-folic acid as a cancer-targeting drug delivery system are prepared by chemical reduction method consisting of two major steps: reduction and stabilization processes. | Spherical particles with a size of 33 ± 9 nm, a size distribution of 0.276 ± 0.050 and a zeta potential of 25.9 ± 0.4 mV are produced. | The in vivo pharmacokinetics analysis in rats depicts that the time to reach maximum plasma drug concentration, drug half-life and AUC of PTX and QUE are higher with pulmonary administration of polymeric microspheres than those of combined or single intravenous administration of PTX and QUE. The clearance and peak plasma drug concentration are lower with the use of pulmonary polymeric microspheres. | Nil | The particles exhibit a higher level of cytotoxicity (6 % cell viability) against lung cancer cells (CHAGO) and are safe (cell viability ≥ 80 %) with reference to normal fibroblast cells of skin (CRL-1947) at 20 μg/mL. GAOBn. Transmission electron microscopy analysis demonstrates that particles are taken up by the lung cancer cells. Chitosan is used to reduce and stabilize the gold nanoparticles. Chitosan is quantified to increase its magnitude of positive charge to enhance its electrostatic interaction with the cancer cells. It is then conjugated with gallic acid as a hydrophobic moiety to increase its permeability, and with folic acid to introduce the active target element for folate receptor overexpressed on the cancer cell surfaces. | (Komenek et al., 2017) |
| F3   | Cisplatin loaded chitosan microspheres are prepared by emulsification and ionotropic gelation method. | Spherical particles with a size of 5.20 ± 1.19 μm, Carr’s index of 28.48 %, moisture and drug contents of 4.10 % and 79.2 ± 2.9 % respectively are produced. Initial burst drug release (37 % in 1 h) followed by sustained release up to 12 h are noted. | The aerodynamic diameter of the microspheres is 2.71 μm. The fine particle fraction of the microspheres is 0.22 μm and can be improved through employing lactose (63 μm–90 μm) as the carrier of the microspheres. | The microspheres are cytotoxic against A549 human lung cancer cells (HOP-62). The microspheres are characterised by a higher IC50 value when compared to free drug due to a slower drug release from the matrix thus negating the drug bioavailability. | Nil | The nanoparticles induce a higher level of cytotoxicity against A549 lung cancer cell line compared to liver cancer HepG2 and Huh-7 cell lines. | (Menon et al., 2012) |
| F4   | Raloxifene loaded hyaluronic acid chitosan nanoparticles are prepared by single emulsion solvent evaporation method. The nanoparticles are a core and surrounded by multilayers of hyaluronic acid- and chitosan-based shell. The nanoparticles are characterized by a size of 210 ± 4.4 nm, a polydispersity index of 0.05 ± 0.00, a zeta potential of -29.1 ± 4.5 mV and a drug encapsulation efficiency of 92 %. | The nanoparticles are constituted of a core and surrounded by multilayers of hyaluronic acid- and chitosan-based shell. The nanoparticles are characterized by a size of 210 ± 4.4 nm, a polydispersity index of 0.05 ± 0.00, a zeta potential of -29.1 ± 4.5 mV and a drug encapsulation efficiency of 92 %. | The nanoparticles induce a higher level of cytotoxicity against A549 lung cancer cell line compared to liver cancer HepG2 and Huh-7 cell lines. | Nil | Hyaluronic acid and chitosan complexation is used to increase the half-life and activity of raloxifene through targeting cluster of differentiation-44 (CD-44) receptor. The significant suppression of A549 lung cancer cell viability is achieved via reducing their glucose uptake to diminish the bioenergetics of cancer cells and activation of apoptosis via nitric oxide level elevation. | (Almutairi et al., 2019) |
| F5   | Nil | Nil | Nil | Nil | Nil | Nil | (continued on next page) |
Table 3 (continued)

| Code | Formulation and Preparation | Physicochemical Property | Aerodynamic Property | Ex Vivo / Cell Culture Performance | In Vivo Performance | Remark | Reference |
|------|-----------------------------|--------------------------|----------------------|-----------------------------------|--------------------|--------|-----------|
| F6   | Docetaxel loaded glutaraldehyde-crosslinked chitosan microspheres are prepared using a water-in-oil emulsification method. | Nanocomposites with a diameter of 50 nm-200 nm are encapsulated in spherical particles having a volume-weighted mean diameter varying from 2.0 μm to 2.9 μm and a span value of 0.8 to 0.9 suitable for deep lung deposition. The drug release propensity is higher at pH 6.8 than pH 7.4. | The particles are characterized by a mass median aerodynamic diameter of approximately 1.5 μm, an emitted fraction above 96% and a fine particle fraction of 55%. |  |  | The higher drug release at pH 6.8 than pH 7.4 is attributed to chitosan, having a pKa value of 6.5, is characterized by partially protonated amine moieties at pH 6.8 leading to particle swelling and thus a faster drug release. The aerosolisation and inhalation of particles exceed the majority of commercial dry powder inhalation formulations. | (Wang et al., 2014) |
| F7   | Gemcitabine loaded surface-tailed chitosan/polyethylene glycol nanoparticles are prepared using ionic gelation method. The nanoparticles encapsulated with gemcitabine are tethered with folic acid. | The particle size and zeta potential of gemcitabine loaded chitosan nanoparticles are 157.2 ± 7.68 nm and 29.3 ± 1.91 mV respectively, whereas gemcitabine loaded surface-tailed polyethylene glycol and folate-polyethylene glycol chitosan nanoparticles are characterized by a size of 165.3 ± 11.0 nm and a zeta potential of 25.1 ± 1.8 mV, and a size of 184.3 ± 12.5 nm and a zeta potential of 21.1 ± 11.8 mV respectively. The drug encapsulation efficiency of gemcitabine loaded, gemcitabine loaded polyethylene glycol, gemcitabine folate-polyethylene glycol chitosan nanoparticles are 40.8 ± 15 %, 37.2 ± 2.2 % and 39.6 ± 2.7 % respectively. The extent of drug released from the nanoparticles over 10 days are nearly 87% (gemcitabine loaded polyethylene glycol chitosan nanoparticles) and 85% (gemcitabine loaded folate-polyethylene glycol chitosan nanoparticles) at pH 5.8 and nearly 79% (gemcitabine loaded polyethylene glycol chitosan nanoparticles) and 75.3% (gemcitabine loaded folate-polyethylene glycol chitosan nanoparticles) at pH 7.4. |  | The higher cellular binding with eventual uptake and cytotoxicity are observed with gemcitabine loaded folate-polyethylene glycol chitosan nanoparticles, presumably facilitated by folate receptor-mediated endocytosis in lung epithelial cancer cell lines (A549 cell). | The half-life of gemcitabine increases from 0.45 ± 0.04 h (free drug) to 3.89 ± 0.13 h and 4.05 ± 0.23 h, respectively with respect to gemcitabine loaded polyethylene glycol chitosan nanoparticles and gemcitabine loaded folate-polyethylene glycol chitosan nanoparticles. The free gemcitabine is not detectable in plasma 12 h post-administration by lateral tail vein route, whereas gemcitabine shielded with a nanoparticulate system is found up to 12 h. A greater quantity of gemcitabine is found in tumour tissues followed by liver and kidney when it is delivered in the form of polyethylene glycol (11.67 ± 1.73 %) and folate-polyethylene glycol (31.33 ± 1.73 %) chitosan nanoparticles after 8 h. The incorporation of gemcitabine into nanoparticles will shield the drug from being metabolized in systemic circulation, and sustain its release from the matrix. Coupling with the use of folate, the drug targeting property of the nanoparticles is enhanced. | (Wang et al., 2017) |

(continued on next page)
| Code | Formulation and Preparation | Physicochemical Property | Aerodynamic Property | Ex Vivo / Cell Culture Performance | In Vivo Performance | Remark | Reference |
|------|-----------------------------|--------------------------|----------------------|-----------------------------------|---------------------|--------|----------|
| F8   | Paclitaxel loaded solid lipid nanoparticles are prepared by using nanoprecipitation method. The nanoparticles are then coated with folate grafted copolymer of polyethylene glycol and chitosan derivative which is N-(2-hydroxy-3-trimethyl ammonium) propyl chitosan chloride. | The nanoparticles exhibit a slow and sustained drug release profile. The nanoparticles are spherical in shape with encapsulation efficiency, mean diameter and zeta potential of about 100 %, 250 nm and +32 mV respectively. Cumulative drug release from the nanoparticles is about 50 % within 3 days of dissolution. After a first burst release of 13 % of drug within 7 h, the drug release rate remains constant, with approximately 15 % of drug released every 24 h. | The nanoparticles enter, or at least bind to two folate receptor-expressing cancer cell lines namely HeLa and M109-HiFR. The HeLa cells are significantly more sensitive to nanoparticles than M109-HiFR cells. The nanoparticles grafted with folate are almost five times more active than the folate-free nanoparticles in M109-HiFR cells and almost three times more active in HeLa cells. | Inhaled folate-grafted nanoparticles exhibit 7-fold and 32-fold increase in pulmonary drug concentrations compared to inhaled taxol following 1 h and 6 h of administration. These nanoparticles are able to reach and penetrate M109-HiFR murine lung carcinoma cell subline in vivo. | Nil | The nanoparticles demonstrate a favourable pharmacokinetics profile, with pulmonary exposure to drug prolonged up to 6 h with limited systemic distribution. (Rosière et al., 2018) |
| F9   | Alginate coated chitosan hollow nanospheres of paclitaxel and doxorubicin are prepared. The paclitaxel is loaded into the nanoscale hollow structure via adsorption process. The positively charged doxorubicin is coated onto the surface of negatively charged hollow nanospheres via electrostatic adsorption. | The drug loadings of paclitaxel and doxorubicin in nanospheres are 18.4 ± 1.32 % and 74.2 ± 3.24 % respectively. The paclitaxel loaded nanospheres show a weakly crystalline diffraction pattern, whereas the doxorubicin loaded nanospheres do not display any crystalline diffraction pattern in comparison to physical mixture and pure drug. | The drug-free nanospheres are non-toxic, whereas the drug loaded nanospheres are cytotoxic against A549 lung cancer cells and induce apoptosis. | Nil | Co-delivery of paclitaxel and doxorubicin can effectively inhibit cell proliferation and promote cell apoptosis due to the nanoscale effect of particles and the synergistic effect of combined drugs. (Tao et al., 2018) |
| F10  | A hybrid system composed of multi-walled carbon nanotubes (MWCNT) coated with chitosan is produced as a pH-responsive carrier of methotrexate. MWCNT are synthesized by fixed-bed chemical vapour deposition method. The fabrication of chitosan-MWCNT (CS-MWCNT) nanohybrid is achieved via precipitation technique. | The use of fixed-bed chemical vapour deposition method produces well defined MWCNT with a narrow size distribution (length in a range of 110 – 980 nm, an average inner diameter of 0.7–1.5 nm, and an outer diameter of 5–8 nm corresponding to 4–7 graphene shells). The coat composition of CS-MWCNT nanohybrid is evident from chemical analysis, Raman spectroscopy and thermogravimetric evaluation. The coat content is about 20 %. The release of methotrexate from nanohybrid follows a pH-responsive behaviour with higher and faster release in acidic (pH 5.5) against neutral (pH 7.4) environments. | Drug-free CS-MWCNT does not affect the viability of H1299 cells (non-small cell lung cancer derived from the lymph node) and MRC-5 cells (fibroblast derived from normal lung tissue). It exhibits a high biocompatibility. The drug loaded CS-MWCNT is highly selective in killing of cancer cells. They are found to possess equal or even more activity on cancer cells than free drugs. The H1299 cells viability is reduced by 15 % when free drug is used in treatment, while the drug loaded CS-MWCNT significantly increases the amount of cell death up to 44 %. | Nil | The CS-MWCNT nanohybrid can selectively deliver the drug to H1299 lung cancer cells with negligible toxicity to healthy MRC-5 cells. This system is successful at reducing side effects of methotrexate to normal tissues and cells. (Cirillo et al., 2019) |
chemotherapeutic (5-fluorouracil) solution for the treatment of non-small cell lung cancer was published (Abdelaziz et al., 2018). Pulmonary administration results in only trace amounts of 5-fluorouracil being detected in plasma with no local or systemic adverse effects. The lung tumor tissues are characterized by 5- to 15-fold higher drug concentrations than normal lung tissues. In another investigation, celecoxib solution is effectively nebulized to treat lung cancer in combination with intravenous docetaxel. The aerosolized celecoxib is therapeutically as effective as oral dosage form, with a lower dose requirement and risk of adverse effect development (Abdelaziz et al., 2018). Despite advantages of pulmonary delivery, the efficacy of inhaled anti-tumor drugs can be limited by branching pattern of the respiratory tract and bio-barriers existing in the respiratory airway systems such as mucus, ciliated cells and resident macrophages limiting the localization, penetration and adsorption of drugs in the lungs (Darquenne, 2012).

Similar to anti-tubercular drugs (Table 2), the chitosan based particulate carriers of anti-cancer drugs are developed by means of ionetic gelation, emulsification and/or spray drying methods (Table 3). Further, nanoprecipitation and chemical vapor deposition are adopted to produce chitosan nanoparticles containing lipid or carbon based composition. Microparticles or microencapsulated nanoparticles are produced to elicit aerodynamic behavior required for pulmonary inhalation (Liu et al., 2017; Rosière et al., 2018; Silva et al., 2017). Targeting ligand such as folate and hyaluronic acid, and permeation enhancer such as gallic acid are introduced to the backbone of chitosan for the purpose of raising the affinity of carrier with cancer target and cellular permeabilisation (Almutairi et al., 2019; Rosière et al., 2018). Quercetin can be used as the p-glycoprotein inhibitor, along with the drug to reduce drug efflux from the cancer cells (Liu et al., 2017). The particle sizes of the carrier for targeting lung tumor are within the range of 50 nm to 9.6 μm (Table 3). The cytotoxicity and cellular uptake of inhaled chitosan based nanoparticles are size dependent. The chitosan based nanoparticles are characterized by positive surface charges (zeta potential values approach +30 mV) and this confers physical stability through reducing particle aggregation by electrical repulsion (Lee et al., 2015a). The endothelial cells of the tumor vasculature are associated with the over-expression of negatively charged surface molecules, for example, anionic phospholipids, glycoproteins and proteoglycans (Jozzo & S anche, 2015; Ran et al., 2002). Electrical interaction between the positively charged chitosan particles and negatively charged endothelial cells of the tumor vasculature can potentiate the accumulation of cationic chitosan particles in the lung tumor capillaries (Honary & Zahir, 2013).

The chitosan, specifically the oligosaccharide variants, exhibits anti-cancer activity (Chokrada jroen et al., 2017; Gibot et al., 2015; Oberemko et al., 2019; Rafael et al., 2019). Its anti-cancer mechanism is generally not known, but it is presumably associated with its electrostatic changes, changes in membrane permeability of cancer cells, regulation of expression of tumor factor such as metalloproteinase-9 and/or their fraction between 2 μm and 3 μm prone to be recognized and eliminated by the resident alveolar macrophages (Lee et al., 2015a). In order to circumvent the above hurdles for the purpose of efficient drug delivery to lung cancer cells, it has been suggested to encapsulate nanoparticles with particle sizes of less than 200 nm into the microparticles with mass median aerodynamic diameters ranging from 3 μm to 5 μm (Dabbagh et al., 2018).

6. Future perspectives

Chitosan and its derivatives are excellent backbone materials of nano and micro particulate carriers for pulmonary delivery of anti-infective and anti-cancer drugs, with respect to their biodegradability, biocompatibility, mucoadhesiveness, anti-microbial, anti-tumour, and permeation enhancement properties. They have been investigated for their suitability of use as the pulmonary particulate carrier lately, deviating from the conventional application of lactose as the main drug carrier. The exploitation of chitosan and derivatives is relatively recent, and requires in depth analysis including in vitro aerodynamic characterisation and in vivo examination of the pharmacokinetics and functionality of these particles through natural inhalation to relate to the actual therapeutic performance.

Infection with SARS-CoV-2 brings about coronavirus disease that leads to acute respiratory distress syndrome, and the patients with cancer appear to be more likely to be diagnosed with COVID-19 (Sidaway, 2020). The late innovations of chitosan have found the therapeutic uses of this biopolymer to combat coronavirus related diseases and cancer. N-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride with an average molecular weight of 250 kDa and degree of substitution between 50 % and 80 % have been shown to exert a strong interaction with the recombinant ectodomain of the S protein of HCoV, thus blocking S protein-host cellular interaction and virus infection (Milewska et al., 2016). Chito-oligosaccharides (molecular weight = 1000–12000 Da, degree of acetylation = 65–70 %), prepared via electrical discharge plasma treatment of chitosan in the liquid state, induce apoptotic death in MCF-7 breast cancer cells (Chokrada jroen et al., 2018). The chito-oligosaccharides have also been found to be effective in killing of PC3 (prostate cancer cells), A549 (lung cancer cells) and HepG2 (hepatoma cells) with lower molecular weights being more effective than larger molecular weight counterparts. The late findings of chitosan and derivatives as therapeutic molecules to treat infection and cancer are envisaged to initiate an intense research interest combining the drug delivery as well as drug discovery attributes of this biomaterials. Their structural-activity relationships in association with coronavirus disease and lung cancer treatment are of great interest from the therapeutic and drug delivery performance viewpoints at molecular levels.
Acknowledgments

The authors wish to express their heartfelt gratitude to Universiti Teknologi MARA (0141903), and Ministry of Higher Education of Malaysia (LRGS-NanoMTte RU029-2014) for fund and facility support.

References

Abdelaziz, H. M., Gaber, M., Abd-Elwali, M. M., Mabrouk, M. T., Elghory, M. M., Kamel, N. M., & Elzohy, A. O. (2018). Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microcapsules, nanocomposites and nanocapsules. Journal of Controlled Release, 269, 374–392.

Agnihotri, S. A., Mallikarjun, N. N., & Aminabhavi, T. M. (2004). Recent advances on chitosan-based micro- and nanoparticles in drug delivery. Journal of Controlled Release, 100(1), S-28.

Ahmed, T. A., & Aljaid, B. M. (2016). Preparation, characterization, and potential application of chitosan, chitin derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. Drug Design, Development and Therapy, 10, 483–507.

Alhajj, N., Chee, C. F., Wong, T. W., Abd Rahman, N., Abu Kasim, N. H., & Colombo, F. (2018). Lung cancer: Active therapeutic targeting and inhalational product design. Expert Opinion on Drug Delivery, 15(12), 1223–1247.

Alnajjar, N., Zakaria, Z., Awang, S., & Clark, B. J. (2010). Evaluation of a nanoemulsion-based sunscreen: Effect on skin hydration and photoprotection. Journal of Pharmacology and Toxicology, 6(3), 1147–1151.

Antonino, R. S. C., Fook, L., Paschal, B. R., De Oliveira Lima, V. A., De Farias Rached, R. I., Lima, E. P. N., & Fia Fook, M. V. (2017). Preparation and characterization of chitosan obtained from shells of shrimp (Litopenaeus vannamei Boone). Marine Drugs, 15(5), 141–152.

Arriagada, R., Bergman, B., Dunant, A., Le Chevalier, T., Pignon, J.-P., Vansteenkiste, J., & International Adjuvant Lung Cancer Trial Collaborative Group (2004). Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. The New England Journal of Medicine, 350(4), 351–360.

Avadi, M. R., Sadeghi, A. M. A., Tahzibi, A., Bayati, K., Pouladzadeh, M., & Zohuriaan-Mehr, M. J. (2014). Dehydromethyl chitosan as an antimicrobial agent: Synthesis, characterization and antibacterial effects. European Polymer Journal, 49(7), 1355–1361.

Azuma, K., Osaki, T., Minami, S., & Okamoto, Y. (2015). Anticancer and anti-inflammatory properties of chitin and chitosan oligosaccharides. Journal of Functional Biomaterials, 6(1), 33–49.

Badawy, M. E. I., Rababa, E. L., Mograby, T. M., Stevens, C. V., Seubert, W., Höfte, M., & Smaghe, G. (2005). Fungalicidal and insecticidal activity of O-acetyl chitosan derivatives. Polymery, 54(4-5), 279–289.

Berkovich, S., & Staab, M. (2001). Effect of chitosan on the bioavailability of low molecular weight drugs. Journal of Controlled Release, 58(2), 127–137.

Bhatia, M., Majumdar, R., & Chakraborty, D. (2019). Bio-based chitosan-based nanocarriers for drug delivery: A systematic review. International Journal of Biological Macromolecules, 141, 476–483.

Bohgardt, J. M., Kloth, C., & Sharma, A. (2018). Inhaled therapy in respiratory disease: The complex interplay of pulmonary kinetic processes. Canadian Respiratory Journal, 2018, 1–11.

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, L. R., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(1), 394–424.

Brenner, D. R., McLaughlin, J. R., & Hung, R. J. (2011). Previous lung diseases and lung cancer. In Brenner, D. R., McLaughlin, J. R., & Hung, R. J. (Eds.), Lung Cancer: A comprehensive reference. Elsevier, pp. 219–246.

Brenner, D. R., McLaughlin, J. R., & Hung, R. J. (2011). Previous lung diseases and lung cancer. In Brenner, D. R., McLaughlin, J. R., & Hung, R. J. (Eds.), Lung Cancer: A comprehensive reference. Elsevier, pp. 219–246.

Brenner, D. R., McLaughlin, J. R., & Hung, R. J. (2011). Previous lung diseases and lung cancer. In Brenner, D. R., McLaughlin, J. R., & Hung, R. J. (Eds.), Lung Cancer: A comprehensive reference. Elsevier, pp. 219–246.

Brenner, D. R., McLaughlin, J. R., & Hung, R. J. (2011). Previous lung diseases and lung cancer. In Brenner, D. R., McLaughlin, J. R., & Hung, R. J. (Eds.), Lung Cancer: A comprehensive reference. Elsevier, pp. 219–246.

Brenner, D. R., McLaughlin, J. R., & Hung, R. J. (2011). Previous lung diseases and lung cancer. In Brenner, D. R., McLaughlin, J. R., & Hung, R. J. (Eds.), Lung Cancer: A comprehensive reference. Elsevier, pp. 219–246.

Brenner, D. R., McLaughlin, J. R., & Hung, R. J. (2011). Previous lung diseases and lung cancer. In Brenner, D. R., McLaughlin, J. R., & Hung, R. J. (Eds.), Lung Cancer: A comprehensive reference. Elsevier, pp. 219–246.
S. S., & Gefuoo, G. M. (2017). Microparticles prepared with 50-190 kDa chitosan as promising non-toxic carriers for pulmonary delivery of ionizid. Carboid Polymers, 174, 421–431.

Ortiz, M., Jornada, D. S., Pohlmann, A. R., & Guterres, S. S. (2015). Development of novel chitosan microparticles for pulmonary delivery of docetaxel: Characterization, animal performance, and in vivo toxicity evaluation. AAPS PharmSciTech, 16(5), 1033–1040.

Pandey, P., Dua, K., & Dureja, H. (2019). Erolinolad loaded chitosan nanoparticles: Formulation, physicochemical characterization and cytotoxic potential. International Journal of Biological Macromolecules, 139, 1304–1314.

Paranjpe, M., & Muller-Goymann, C. C. (2014). Nanoparticle-mediated pulmonary drug delivery: A review. International Journal of Molecular Sciences, 15(4), 5852–5873.

Park, J. H., Saravanakumar, G., Kim, K., & Kwon, I. C. (2010). Targeted delivery of low molecular weight drugs using chitosan and its derivatives. Advanced Drug Delivery Reviews, 62(1), 28–41.

Patel, B., Gupta, N., & Ahsan, F. (2015). Particle engineering to enhance or lessen uptake by alveolar macrophages and to influence therapeutic outcomes. European Journal of Pharmaceutics and Biopharmaceutics, 95, 163–174.

Paumier, A., & Le Peuchoux, C. (2010). Radiotherapy in small-cell lung cancer: Where should it go? Lung Cancer, 69(2), 133–140.

Pekar, K. C., Chavhan, S., Kunda, N., Salmen, I., Somavarapu, S., Taylor, K. G. M., & Savant, K. K. (2018). Development of novel octylchitosan nanoparticles for improved rifampicin pulmonary delivery: Optimization by factorial design. AAPS PharmSciTech, 19(4), 1758–1772.

Pham, D. D., Fattal, E., & Tsapis, N. (2015). Pulmonary drug delivery systems for tuberculosis treatment. International Journal of Pharmaceutics, 478(2), 517–529.

Pilger, G., & Amighi, K. (2010). Formulation strategy and use of excipients in pulmonary drug delivery. International Journal of Pharmaceutics, 392(1–2), 1–19.

Plata, C., Zelnitz, N., Robles, T., Robles, E. P. A., & Palma, R. O. A. (2013). Assessment of dry powder inhaler carrier target design: A comparative case study of diverse anionic compositions and physical properties of lactose. Molecular Pharmacology, 15(7), 2827–2839.

Pires, C., Cunha, P. L. R., Maciel, J. S., Angelim, A. L., Meio, V. M. M., de Paula, R. C. M., & Feitosa, J. P. A. (2013). Sulfated chitosan as tear substitute with no anti-microbial activity. Carboid Polymers, 91(1), 92–99.

Pourshahab, P. S., Gilani, K., Moazeni, E., Eslahi, H., Fazeli, M. R., & Jamalifar, H. (2011). Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of ionizid. Journal of Microencapsulation, 28(7), 605–613.

Qiao, Y., Lai, J. W., Leung, S. W. S., & Liang, W. (2016). Delivery of RNAi therapeutics through nose-to-bronchus route. Molecules, 21(9), 1249–1280.

Quiñones, J. P., Peniche, H., & Peniche, C. (2018). Chitosan based self-assembled nanoparticles in drug delivery. Polymers, 10(3), 235–266.

Raba, E. L., Badawy, M. E. T., Stevens, C. V., Smagghe, G., & Steurbaut, W. (2003). Chitosan as antimicrobial agent: Applications and mode of action. Biomacromolecules, 4(6), 1457–1465.

Rafael, O. H. D., Fernando, Z. G. L., Abraham, P. T., Alberto, V. L. P., Guadalupe, G. S., & Pablos, P. J. (2019). Production of chitosan-oligosaccharides by the chitin-hydrolytic enzyme Chitinasium sp. strain F775 and their potential as coatings to control bacterial adhesion and biofilm formation. Carbohydrate Polymers, 164, 327–330.

Renger, N., Steckel, H., Urbanetz, N., & Scherließ, R. (2014). Nano- and microstructured model carrier surfaces to alter dry powder inhaler performance. International Journal of Pharmaceutics, 498(1–2), 20–28.

Rodrigues, S., Dionisio, M., Lopes, C. R., & Grzheb, A. (2012). Biocompatibility of chitosan carriers with application in drug delivery. Journal of Functional Biomaterials, 3(3), 615–641.

Roldo, M., Hornof, M., Caliceti, P., & Bernkop-Schnürch, A. (2004). Mucoadhesive thiochitosan nanoparticles in drug delivery: From bench to bedside. International Journal of Pharmaceutics, 289, 89–105.

Roldo, M., Hornof, M., Caliceti, P., & Bernkop-Schnürch, A. (2004). Mucoadhesive thiochitosan nanoparticles in drug delivery: From bench to bedside. International Journal of Pharmaceutics, 289, 89–105.

Roldo, M., Hornof, M., Caliceti, P., & Bernkop-Schnürch, A. (2004). Mucoadhesive thiochitosan nanoparticles in drug delivery: From bench to bedside. International Journal of Pharmaceutics, 289, 89–105.

Roldo, M., Hornof, M., Caliceti, P., & Bernkop-Schnürch, A. (2004). Mucoadhesive thiochitosan nanoparticles in drug delivery: From bench to bedside. International Journal of Pharmaceutics, 289, 89–105.

Roldo, M., Hornof, M., Caliceti, P., & Bernkop-Schnürch, A. (2004). Mucoadhesive thiochitosan nanoparticles in drug delivery: From bench to bedside. International Journal of Pharmaceutics, 289, 89–105.

Roldo, M., Hornof, M., Caliceti, P., & Bernkop-Schnürch, A. (2004). Mucoadhesive thiochitosan nanoparticles in drug delivery: From bench to bedside. International Journal of Pharmaceutics, 289, 89–105.

Roldo, M., Hornof, M., Caliceti, P., & Bernkop-Schnürch, A. (2004). Mucoadhesive thiochitosan nanoparticles in drug delivery: From bench to bedside. International Journal of Pharmaceutics, 289, 89–105.

Roldo, M., Hornof, M., Caliceti, P., & Bernkop-Schnürch, A. (2004). Mucoadhesive thiochitosan nanoparticles in drug delivery: From bench to bedside. International Journal of Pharmaceutics, 289, 89–105.

Roldo, M., Hornof, M., Caliceti, P., & Bernkop-Schnürch, A. (2004). Mucoadhesive thiochitosan nanoparticles in drug delivery: From bench to bedside. International Journal of Pharmaceutics, 289, 89–105.

Roldo, M., Hornof, M., Caliceti, P., & Bernkop-Schnürch, A. (2004). Mucoadhesive thiochitosan nanoparticles in drug delivery: From bench to bedside. International Journal of Pharmaceutics, 289, 89–105.

Roldo, M., Hornof, M., Caliceti, P., & Bernkop-Schnürch, A. (2004). Mucoadhesive thiochitosan nanoparticles in drug delivery: From bench to bedside. International Journal of Pharmaceutics, 289, 89–105.

Roldo, M., Hornof, M., Caliceti, P., & Bernkop-Schnürch, A. (2004). Mucoadhesive thiochitosan nanoparticles in drug delivery: From bench to bedside. International Journal of Pharmaceutics, 289, 89–105.

Roldo, M., Hornof, M., Caliceti, P., & Bernkop-Schnürch, A. (2004). Mucoadhesive thiochitosan nanoparticles in drug delivery: From bench to bedside. International Journal of Pharmaceutics, 289, 89–105.

Roldo, M., Hornof, M., Caliceti, P., & Bernkop-Schnürch, A. (2004). Mucoadhesive thiochitosan nanoparticles in drug delivery: From bench to bedside. International Journal of Pharmaceutics, 289, 89–105.
Yadav, A. B., Sharma, R., Muttil, P., Singh, A. K., Verma, R. K., Mohan, M., & Misra, A. (2009). Inhalable microparticles containing isoniazid and rifabutin target macrophages and “stimulate the phagocyte” to achieve high efficacy. *Indian Journal of Experimental Biology, 47*(6), 469–474.

Yang, M. Y., Chan, J. G. Y., & Chan, H.-K. (2014). Pulmonary drug delivery by powder aerosols. *Journal of Controlled Release, 193*, 228–240.

Yang, W., Peters, J. I., & Williams, R. O. (2014). Inhaled nanoparticles-A current review. *International Journal of Pharmaceutics, 356*, 239–247.

Yeh, T. H., Hsu, I. W., Tseng, M. T., Lee, P. L., Sonjae, K., Ho, Y. C., & Sung, H. W. (2014). Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. *Biomaterials, 32*(26), 6164–6173.

Yıldız-Pekoz, A., Akbal, O., Tekarslan, S. H., Sagrili, A. O., Mullaznimoglu, L., Morina, D., & Cevher, E. (2016). Preparation and characterization of doripenem-loaded microparticles for pulmonary delivery. *Journal of Aerosol Medicine and Pulmonary Drug Delivery, 31*(6), 347–357.

Yang, G. Q., Xiong, W. Y., Wang, H., Sun, Y., & Liu, H. Z. (2011). Preparation, water solubility and antioxidant activity of branched-chain chitosan derivatives. *Carbohydrate Polymers, 83*(4), 1787–1796.

Youngren-Ortiz, S. R., Gandhi, N. S., España-Serrano, L., & Chougule, M. B. (2016). *Aerosol delivery of siRNA to the lungs. Part 1: Rationale for gene delivery systems. KONA Powder and Particle Journal, 2016*(33), 63–85.

Zariwala, M. G., Bendre, H., Markiv, A., Farnaad, S., Renshaw, D., Taylor, K. M. G., & Somavarapu, S. (2018). Hydrophobically modified chitosan nanoparticles for intestinal drug delivery. *International Journal of Nanomedicine, 13*, 5837–5848.

Zeng, X. M., Martin, G. P., Marriott, C., & Pritchard, J. (2000). The influence of carrier morphology on drug delivery by dry powder inhalers. *International Journal of Pharmaceutics, 200*(1), 93–106.

Zeng, X., Martin, G. P., Marriott, C., & Pritchard, J. (2001). Lactose as a carrier in dry powder formulations: The influence of surface characteristics on drug delivery. *Journal of Pharmaceutical Sciences, 90*(9), 1424–1434.

Zhang, J., Xia, W., Liu, P., Cheng, Q., Tahirou, T., Gu, W., & Li, B. (2010). Chitosan modification and pharmaceutical/biomedical applications. *Marine Drugs, 8*(7), 1962–1987.

Zhang, K., Peschel, D., Helm, J., Groth, T., & Fischer, S. (2011). FT Raman investigation of novel chitosan sulfates exhibiting osteogenic capacity. *Carbohydrate Polymers, 83*(1), 60–65.

Zhang, Y., Chan, J. W., Moretti, A., & Ulrich, K. E. (2015). Designing polymers with sugar-based advantages for bioactive delivery applications. *Journal of Controlled Release, 219*, 355–368.

Zhou, Q. T., & Morton, D. A. V. (2012). Drug–Lactose binding aspects in adhesive mixtures: Controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces. *Advanced Drug Delivery Reviews, 64*(3), 275–284.

Zhu, A.-P. P., & Fang, N. (2005). Adhesion dynamics, morphology, and organization of 3T3 fibroblast on chitosan and its derivative: The effect of O-carboxymethylation. *Biomacromolecules, 6*(5), 2607–2614.

Zhu, H., Luo, W., Ciesielski, P. N., Fang, Z., Zhu, J. Y., Henriksson, G., & Hu, L. (2016). Wood-derived materials for green electronics, biological devices, and energy applications. *Chemical Reviews, 116*(10), 9305–9374.